ProShare Advisors’s Anavex Life Sciences AVXL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $51.7K | Sell |
16,829
-2,395
| -12% | -$10.4K | ﹤0.01% | 1780 |
|
|
2025
Q4 | $68.4K | Buy |
19,224
+1,870
| +11% | +$11.5K | ﹤0.01% | 1922 |
|
|
2025
Q3 | $154K | Sell |
17,354
-2,976
| -15% | -$30.2K | ﹤0.01% | 1759 |
|
|
2025
Q2 | $187K | Buy |
20,330
+249
| +1% | +$2.13K | ﹤0.01% | 1737 |
|
|
2025
Q1 | $172K | Sell |
20,081
-5,066
| -20% | -$47.8K | ﹤0.01% | 1734 |
|
|
2024
Q4 | $270K | Buy |
25,147
+5,958
| +31% | +$45.8K | ﹤0.01% | 1713 |
|
|
2024
Q3 | $109K | Buy |
19,189
+4,284
| +29% | +$24.7K | ﹤0.01% | 1864 |
|
|
2024
Q2 | $62.9K | Sell |
14,905
-3,837
| -20% | -$15.5K | ﹤0.01% | 1720 |
|
|
2024
Q1 | $95.4K | Buy |
18,742
+1,532
| +9% | +$8.62K | ﹤0.01% | 1830 |
|
|
2023
Q4 | $160K | Buy |
17,210
+2,589
| +18% | +$17.8K | ﹤0.01% | 1687 |
|
|
2023
Q3 | $95.8K | Buy |
14,621
+259
| +2% | +$2.06K | ﹤0.01% | 1639 |
|
|
2023
Q2 | $117K | Buy |
14,362
+813
| +6% | +$6.97K | ﹤0.01% | 1674 |
|
|
2023
Q1 | $116K | Sell |
13,549
-1,796
| -12% | -$17.9K | ﹤0.01% | 1565 |
|
|
2022
Q4 | $142K | Buy |
15,345
+1,165
| +8% | +$12.4K | ﹤0.01% | 1577 |
|
|
2022
Q3 | $146K | Buy |
14,180
+486
| +4% | +$5.13K | ﹤0.01% | 1471 |
|
|
2022
Q2 | $136K | Sell |
13,694
-6,767
| -33% | -$64.1K | ﹤0.01% | 1555 |
|
|
2022
Q1 | $251K | Sell |
20,461
-4,899
| -19% | -$60.2K | ﹤0.01% | 1753 |
|
|
2021
Q4 | $440K | Buy |
+25,360
| New | +$482K | ﹤0.01% | 1549 |
|
|
2021
Q3 | – | Sell |
-16,100
| Closed | -$368K | – | 2027 |
|
|
2021
Q2 | $368K | Buy |
16,100
+465
| +3% | +$6.89K | ﹤0.01% | 1753 |
|
|
2021
Q1 | $234K | Buy |
15,635
+4,006
| +34% | +$43.8K | ﹤0.01% | 1944 |
|
|
2020
Q4 | $63K | Buy |
+11,629
| New | +$61.3K | ﹤0.01% | 2032 |
|
Other funds holding AVXL
VCM
SF
VPM